Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zelira Therapeutics (ZLDAF)
OTHER OTC:ZLDAF
Holding ZLDAF?
Track your performance easily
ZLDAF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.16 - $0.73
Previous Close$0.45
Volume85.00
Average Volume (3M)1.69K
Market Cap
$4.87M
Enterprise Value$3.73M
Total Cash (Recent Filing)AU$2.75M
Total Debt (Recent Filing)AU$500.91K
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Feb 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.10
Shares Outstanding9,577,116
10 Day Avg. Volume108
30 Day Avg. Volume1,690
Standard Deviation0.35
R-Squared0.07
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)454.20
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Zelira Therapeutics News
PremiumCompany Announcements
Zelira Therapeutics Issues Convertible Notes
PremiumCompany Announcements
Zelira Therapeutics Issues 3.5 Million Convertible Notes
PremiumCompany Announcements
Zelira Therapeutics Unveils Growth Plans at Investment Conference
PremiumCompany Announcements
Zelira Therapeutics Secures Shareholder Support at AGM
PremiumCompany Announcements
Zelira Therapeutics Prepares for 2024 Shareholders Meeting
PremiumCompany Announcements
Zelira Therapeutics’ Financials: Borrowings Boost Cash Flow
PremiumCompany Announcements
Zelira Therapeutics Advances in FDA Trials and Product DevelopmentPremiumCompany Announcements
Zelira Therapeutics Schedules Hybrid 2024 AGMZLDAF FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest stock price was $0.16 and its highest was $0.73 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Currently, no data Available
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 59 days.
How were Zelira Therapeutics’s earnings last quarter?
Zelira Therapeutics released its earnings results on Aug 28, 2024. The company reported -$0.139 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.139.
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,347,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Zelira Therapeutics reported an EPS of -$0.139 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.692%.
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in ZLDAF
---
Zelira Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
ZLDAF Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.86%
12-Months-Change
Fundamentals
Return on Equity
-263.02%
Trailing 12-Months
Asset Growth
-84.65%
Trailing 12-Months
Company Description
Zelira Therapeutics
Zelira Therapeutics Ltd, formerly Zelda Therapeutics Ltd is an Australia-based biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in a breast, brain, and pancreatic cancer.
---
Technical Analysis
---